Effect of interleukin 1β inhibition in cardiovascular disease

Current Opinion in Lipidology

Volumn 23, Issue 6, 2012, Pages 548-553

  Qamar, Arman ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

atherosclerosis; canakinumab; cytokines; IL 1 ; inflammation

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CHOLESTEROL; CRYOPYRIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN A1C; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSUVASTATIN; TRIAMCINOLONE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CORONARY ARTERY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM INJURY; GENE DELETION; GOUT; HUMAN; INFLAMMATION; LOSS OF FUNCTION MUTATION; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MOLECULAR TARGETED THERAPY;

ANIMALIA; MUS;

EID: 84870066624     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328359b0a6     Document Type: Review

References (53)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
2. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque. Part I: Evolving concepts. J Am Coll Cardiol 2005; 46:937-954. (Pubitemid 41316498)
3. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129-2138.
4. Hansson GK, Libby P. The immune response in atherosclerosis: a doubleedged sword. Nat Rev Immunol 2006; 6:508-519. (Pubitemid 43980523)
5. Dong ZM, Chapman SM, Brown AA, et al. The combined role of P-and E-selectins in atherosclerosis. J Clin Invest 1998; 102:145-152. (Pubitemid 28323841)
6. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107:1255-1262. (Pubitemid 32494542)
7. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011; 41:1203-1217. A comprehensive up-do-date review of IL-1b and its role in inflammation.
8. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest 2009; 119:3502-3511.
9. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821-832.
10. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13:323-340.
11. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-2437.
12. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360: 2438-2444.
13. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-2425.
14. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-860.
15. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866-873.
16. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241. (Pubitemid 43372104)
17. Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160:618-623. (Pubitemid 14052522)
18. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:656-660. (Pubitemid 36438080)
19. Chamberlain J, Evans D, King A, et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol 2006; 168:1396-1403.
20. Merhi-Soussi F, Kwak BR, Magne D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005; 66:583-593. (Pubitemid 40725770)
21. Isoda K, Shiigai M, Ishigami N, et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation 2003; 108:516-518. (Pubitemid 36961162)
22. Isoda K, Sawada S, Ishigami N, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24:1068-1073. (Pubitemid 38737833)
23. Chamberlain J, Gunn J, Francis S, et al. Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries. Cardiovasc Res 1999; 44:156-165. (Pubitemid 29431693)
24. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 1996; 97:769-776. (Pubitemid 26057096)
25. Morton AC, Arnold ND, Gunn J, et al. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc Res 2005; 68:493-501. (Pubitemid 41566569)
26. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361. This seminal paper demonstrated that NLRP3 inflammasomes are activated by cholesterol crystals generating IL-1 b and that genetic inactivation of this pathway reduces atherosclerosis in mice. It put forth a direct mechanistic link between cholesterol, IL-1b, and atherosclerosis.
27. Rajamaki K, Lappalainen J, Oorni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010; 5:e11765.
28. Alexander MR, Moehle CW, Johnson JL, et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 2012; 122:70-79. Alexander et al. use mice deficient in the IL-1 receptor type I and examine late atherosclerotic lesions in atherosclerosis-prone mice. The atherosclerotic vessels have impaired outward remodeling and reduced lumen size, suggesting a potential role for IL-1b signaling in vascular remodeling associated with atherosclerosis. This illustrates the complexity of IL-1 b pathway in atherogenesis.
29. Rader DJ. IL-1 and atherosclerosis: a murine twist to an evolving human story. J Clin Invest 2012; 122:27-30.
30. Dalekos GN, Elisaf M, Bairaktari E, et al. Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med 1997; 129:300-308. (Pubitemid 27169432)
31. Fearon WF, Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 2008; 117:2577-2579.
32. Galea J, Armstrong J, Gadsdon P, et al. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996; 16:1000-1006. (Pubitemid 26266899)
33. Olofsson PS, Sheikine Y, Jatta K, et al. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis. Circ J 2009; 73:1531-1536.
34. Patti G, D'Ambrosio A, Dobrina A, et al. Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. J Thromb Thrombolysis 2002; 14:139-143. (Pubitemid 36559680)
35. Patti G, Di Sciascio G, D'Ambrosio A, et al. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002; 89:372-376. (Pubitemid 34142508)
36. Patti G, D'Ambrosio A, Mega S, et al. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43:35-38. (Pubitemid 38045911)
37. Francis SE, Camp NJ, Dewberry RM, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999; 99:861-866. (Pubitemid 29094297)
38. Kastrati A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000; 36:2168-2173.
39. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
40. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7 (SUPPL. 1):332-339.
41. Waugh J, Perry CM. Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 2005; 19:189-202.
42. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526. (Pubitemid 46588416)
43. Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32:1663-1668.
44. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009; 11:81-89.
45. Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011; 12:153.
46. Rissanen A, Howard CP, Botha J, Thuren T. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012.
47. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012.
48. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-316.
49. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70:2095-2102.
50. Curran MP. Canakinumab: in patients with cryopyrin-associated periodic syndromes. BioDrugs 2012; 26:53-59.
51. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008; 117:2662-2669.
52. Crossman DC, Morton AC, Gunn JP, et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 2008; 9:8.
53. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162:597-605. Ridker et al. describe the inflammatory hypothesis of atherosclerosis and the design of a clinical trial, CANTOS, to test the hypothesis that IL-1b inhibition will improve cardiovascular outcomes.